Abstract
rTMS is approved by FDA for treatment of drug-resistant depression, and has been shown to be useful in cases where antidepressant treatment is complicated by intolerable side effects. The success rate of rTMS was reported to be above 70%. Improved gait speed and motor functioning have been recorded in patient with Parkinson’s disease (PD) when high frequency rTMS is delivered over the motor areas of the cortex. Index case was a 74-year old man with 6 years history of Depression and 1 year history of Parkinson’s disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
